Stock Comparison
HALO vs REGN
Halozyme Therapeutics Inc and Regeneron Pharmaceuticals Inc side by side — valuation, profitability, growth and risk.
Valuation
Market Cap
$12.00B
$80.55B
P/E (TTM)
29.7
19.4
Forward P/E
14.0
17.1
Price/Sales
7.2
5.2
Price/Book
83.6
2.5
EV/EBITDA
19.5
13.1
Dividend Yield
—
0.45%
Profitability
Net Margin
23.13%
29.65%
Operating Margin
56.96%
24.32%
Return on Equity
173.70%
14.00%
Return on Assets
25.50%
6.53%
Growth (YoY)
Revenue Growth
47.70%
16.70%
Earnings Growth
42.90%
-4.50%
Price & Risk
Beta
0.8
0.2
52-Week High
$103.12
$810.12
52-Week Low
$61.63
$553.38
Analyst Target
$88.22
$833.54
Compare HALO and REGN your own way
Try mrmarket.ai freeFigures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.